Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab + S-1 + anlotinib as adjuvant therapy after radical resection of biliary tract cancer
ChiCTR2500103904Phase 2Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Start
- Jun 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sintilimab, tegafur and anlotinib in biliary cancer, sponsored by The First Affiliated Hospital of Zhengzhou University. Primary endpoint: 2-year recurrence-free survival rate. Planned start Jun 2025; status: not yet recruiting.
02
Drugs
sintilimabtegafuranlotinib
03
Conditions
biliary cancer
Beyond the preview
Go deeper on ChiCTR2500103904.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500103904.